Literature DB >> 15647635

Yeast metabolic products, yeast antigens and yeasts as possible triggers for irritable bowel syndrome.

Heiko Santelmann1, John McLaren Howard.   

Abstract

Many patients with irritable bowel syndrome (IBS) are disillusioned by the lack of efficacy of treatments and suffer from numerous symptoms not covered by the Rome criteria for IBS, as the current empirical treatment regimens fail to address these persistent debilitating 'IBS associated symptoms'. These symptoms are similar to other symptom complexes like chronic fatigue and the so-called 'candida syndrome', and many seek help from alternative medicine. The possible role of Candida and yeasts in non-immune compromised individuals is disputed and is the subject of this review. Even if the involvement of yeasts in the aetiology of IBS still remains unclear, there is increasing evidence for yeasts being able to cause IBS-symptoms in sensitized patients via Candida products, antigens and cross-antigens. But more research is needed before antifungal treatment can be recommended as a first line treatment for IBS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15647635     DOI: 10.1097/00042737-200501000-00005

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  20 in total

1.  The Adaptor Protein CARD9 Protects against Colon Cancer by Restricting Mycobiota-Mediated Expansion of Myeloid-Derived Suppressor Cells.

Authors:  Tingting Wang; Chaogang Fan; Anran Yao; Xingwei Xu; Guoxing Zheng; Yun You; Changying Jiang; Xueqiang Zhao; Yayi Hou; Mien-Chie Hung; Xin Lin
Journal:  Immunity       Date:  2018-09-18       Impact factor: 31.745

Review 2.  Need for a comprehensive medical approach to the neuro-immuno-gastroenterology of irritable bowel syndrome.

Authors:  Pejman Katiraei; Gilberto Bultron
Journal:  World J Gastroenterol       Date:  2011-06-21       Impact factor: 5.742

3.  Gut mycobiota and adenomas.

Authors:  Chunguang Luan; Huifang Miao; Baoli Zhu
Journal:  Gut Microbes       Date:  2015

Review 4.  The first 1000 cultured species of the human gastrointestinal microbiota.

Authors:  Mirjana Rajilić-Stojanović; Willem M de Vos
Journal:  FEMS Microbiol Rev       Date:  2014-06-27       Impact factor: 16.408

Review 5.  The role of fungi in C. difficile infection: An underappreciated transkingdom interaction.

Authors:  David Stewart; Jesus A Romo; Regina Lamendella; Carol A Kumamoto
Journal:  Fungal Genet Biol       Date:  2019-04-10       Impact factor: 3.495

Review 6.  Mycobiota in gastrointestinal diseases.

Authors:  Pranab K Mukherjee; Boualem Sendid; Gautier Hoarau; Jean-Frédéric Colombel; Daniel Poulain; Mahmoud A Ghannoum
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-11-11       Impact factor: 46.802

7.  Fungal infection in a patient with multiple sclerosis.

Authors:  D Pisa; R Alonso; L Carrasco
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-05-01       Impact factor: 3.267

8.  Gut dysbiosis promotes M2 macrophage polarization and allergic airway inflammation via fungi-induced PGE₂.

Authors:  Yun-Gi Kim; Kankanam Gamage Sanath Udayanga; Naoya Totsuka; Jason B Weinberg; Gabriel Núñez; Akira Shibuya
Journal:  Cell Host Microbe       Date:  2014-01-15       Impact factor: 21.023

9.  Effect of breadmaking process on in vitro gut microbiota parameters in irritable bowel syndrome.

Authors:  Adele Costabile; Sara Santarelli; Sandrine P Claus; Jeremy Sanderson; Barry N Hudspith; Jonathan Brostoff; Jane L Ward; Alison Lovegrove; Peter R Shewry; Hannah E Jones; Andrew M Whitley; Glenn R Gibson
Journal:  PLoS One       Date:  2014-10-30       Impact factor: 3.240

10.  IgG and IgG4 antibodies in subjects with irritable bowel syndrome: a case control study in the general population.

Authors:  Solveig C Ligaarden; Stian Lydersen; Per G Farup
Journal:  BMC Gastroenterol       Date:  2012-11-21       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.